在系統(tǒng)回顧、梳理清宣止咳顆粒上市以來的臨床及基礎(chǔ)研究成果的基礎(chǔ)上，采用國際臨床醫(yī)學(xué)專家共識(shí)研制方法，通過召開專家論證會(huì)及函審，結(jié)合現(xiàn)有循證證據(jù)制定本專家共識(shí)。共識(shí)對(duì)清宣止咳顆粒治療兒童感冒、支氣管炎的優(yōu)勢(shì)環(huán)節(jié)、給藥方案與劑量療程特點(diǎn)、安全性問題等進(jìn)行了推薦或建議，并通過專家會(huì)議以及函審的方式，在全國范圍內(nèi)進(jìn)行意見征求和同行評(píng)議，可為指導(dǎo)清宣止咳顆粒的臨床合理用藥提供參考。

On the basis of systematic review and sorting out the clinical and basic research achievements of Qingxuan Zhike Granule since its listing, the international clinical medical expert consensus development method was adopted. This expert consensus was developed by holding expert review meetings and letter reviews, combined with existing evidence-based evidence. This consensus has recommended or suggested the advantages of Qingxuan Zhike Granule in treating children's colds and bronchitis, the characteristics of drug delivery scheme and dosage course, and safety issues, and has solicited opinions and peer reviews nationwide through expert meetings and letter reviews, which can provide reference for guiding the rational clini‐ cal use of Qingxuan Zhike Granule.

R285.5